Cancer is among the leading causes of death worldwide. In 2018, there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide. With the advancement of next generation sequencing (NGS) technology, using NGS panels for cancer research becomes the top choice for oncology field. While the cost and turnaround time of the NGS testing have decreased dramatically, reporting of NGS results still faces many challenges. In this regard, a powerful reporting software is essential for generating comprehensive NGS reports that meet laboratory specific requirements. Oncomine Reporter is such a tool with the following wonderful features: 1. Managing and interpreting the significance of the variants in a desired format; 2. Curating the variants for their use of on-market oncology drugs; 3. Providing published evidence from NCCN, FDA, EMA and ESMO, etc. and current global clinical trials; 4. Saving time for the research of published evidence and composing of the report; 5. Updating knowledge base content monthly; 6. Special handling of variants such as FLT3 ITD, MET Exon 14 skipping, and resistance mutations; 7. Easy navigating including batch vs. single case analysis and options for customization of a branded report for each institution. This presentation will give you an overview of the importance of using Oncomine Reporter for oncology NGS reporting and demonstrate the features of Oncomine Reporter through case studies.
1. Be able to describe the importance of using a powerful tool for oncology NGS reporting
2. Be able to demonstrate the features of Oncomine Reporter through case studies